Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-18T00:56:14.583Z Has data issue: false hasContentIssue false

Lamotrigine-Induced Toxidermia

Published online by Cambridge University Press:  31 July 2026

K. Taleb*
Affiliation:
Psychiatry, Arrazi hospitalRazi Hospital
F. Laajili
Affiliation:
Arrazi hospital, Salé, Morocco
B. Hana
Affiliation:
Razi Hospital
Z. Bencharfa
Affiliation:
Arrazi hospital, Salé, Morocco
F. El Omari
Affiliation:
Arrazi hospital, Salé, Morocco
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Introduction

Lamotrigine, widely used in bipolar and depressive disorders, may rarely cause severe cutaneous adverse reactions such as DRESS syndrome. Early recognition is crucial to prevent severe complications.

Objectives

To report a case of lamotrigine-induced DRESS syndrome and emphasize the importance of early detection and careful monitoring to prevent severe complications.

Methods

Case Report: A 19-year-old female treated for recurrent depressive disorder was started on lamotrigine (50 mg/day). Six weeks later, she developed a diffuse pruritic maculopapular rash, fever (38.5°C), cervical lymphadenopathy, and fatigue.

Laboratory tests showed eosinophilia (1200/μL) and moderate hepatic cytolysis (AST 85 U/L, ALT 92 U/L).

The RegiSCAR score suggested probable DRESS. Lamotrigine was promptly discontinued, and systemic corticosteroids were introduced, leading to rapid improvement and resolution of skin lesions within 10 days.

Results

Discussion DRESS is a rare but potentially fatal drug-induced reaction, typically occurring 2–8 weeks after exposure. The risk increases with rapid dose escalation or valproate co-administration.

Management includes immediate drug withdrawal, symptomatic treatment, and systemic corticosteroids in severe cases.

Conclusions

Ce cas souligne la nécessité d’une surveillance étroite lors de l’instauration du traitement par lamotrigine.

Tout signe d’alerte cutané ou systémique doit inciter à une évaluation urgente afin de prévenir les complications graves liées au syndrome DRESS.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.